Keywords: gsk/synta, elesclomol, good, ph, ii, glaxosmithkline, synta
GSK/Synta's elesclomol good in Ph II
Article | 26 May 2008
GlaxoSmithKline and Synta Pharmaceuticals have announced positive Phase II clinical data for elesclomol (formerly STA-4783), an investigational agent currently in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
